New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 18, 2019 - The FDA approved Samsung Bioepis and Merck’s Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin® (trastuzumab).
Download PDF
Return to publications
